[FDA, Friday September 2, 2016]
“Companies will no longer be able to market antibacterial washes with these ingredients because manufacturers did not demonstrate that the ingredients are both safe for long-term daily use and more effective than plain soap and water in preventing illness and the spread of certain infections.”

“This final rule applies to consumer antiseptic wash products containing one or more of 19 specific active ingredients, including the most commonly used ingredients – triclosan and triclocarban.”
“Consumers may think antibacterial washes are more effective at preventing the spread of germs, but we have no scientific evidence that they are any better than plain soap and water,” said Janet Woodcock, M.D., director of the FDA’s Center for Drug Evaluation and Research. “In fact, some data suggests that antibacterial ingredients may do more harm than good over the long-term.”

[FDA, December 24, 2013]
“……antibacterial soap products contain chemical ingredients, such as triclosan and triclocarban, which may carry unnecessary risks given that their benefits are unproven.”

“New data suggest that the risks associated with long-term, daily use of antibacterial soaps may outweigh the benefits,” Rogers says. There are indications that certain ingredients in these soaps may contribute to bacterial resistance to antibiotics, and may have unanticipated hormonal effects that are of concern to FDA.”


“In April, the WHO declared that the problem “threatens the achievements of modern medicine. A post-antibiotic era — in which common infections and minor injuries can kill — is a very real possibility for the 21st century.”
“……a report on antibiotic resistance linked to an executive order from President Barack Obama, who directed the National Security Council to work with a governmental task force and a nongovernmental advisory council to develop a national action plan by February 2015.”
“…..antibiotics in a market that is currently worth more than $40 billion annually for drugs that are starting to fail.

C.Nathan, M.D., et al
Resistance — Problems, Progress, and Prospects
New England Journal Of Medicine…..volume 371 #19…..November 6, 2014….page 1761 – 1763


[CNBC, December 11, 2014…..Drug resistance deadlier than cancer by 2050……by Catherine Boyle]
“Infections resistant to medicines will kill more people per year than cancer by 2050, and cost the world $100 trillion annually, according to a U.K. government-backed report led by Jim O’Neill, the well-known former Goldman Sachs economist.”
“The wide-ranging study, called the Review on Antimicrobial Resistance, was commissioned by the U.K. government earlier this year amid growing concerns about drug-resistant “superbugs”, including new strains of E. coli, malaria and tuberculosis.”.
“Its forecasts, based on research by RAND Europe and KPMG, suggest that drug resistance, which is estimated to have caused around 700,000 deaths globally this year, will cause 10 million by 2050 if further action is not taken.”